In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Diagnostics Boosts Staff To Focus On Medical Genomics Research

This article was originally published in The Gray Sheet

Executive Summary

Roche Diagnostics will bolster its genetic research efforts by adding a 100-person genomics staff as it seeks to capitalize on advances being made in the genomics field by shifting its R&D focus from clinical chemistry to molecular genetics.

You may also be interested in...

MiniMed To File Home-Use Continuous Glucose Monitor PMA In Early 2000

MiniMed is developing a follow-on version of its continuous glucose monitoring system (CGMS) that will be sold directly to patients, allowing them to monitor their own glucose levels, the firm said following FDA's June 16 approval of a non-consumer configuration as an adjunct to finger-stick blood glucose testing.

Roche Cedes CEDIA DOA Reagents, Seals Corange Deal March 5

Roche is negotiating with potential buyers of Boehringer Mannheim's Closed Enzyme Donor Immuno Assay (CEDIA) reagents for drugs-of-abuse (DOA) testing to comply with conditions of a Feb. 24 Federal Trade Commission settlement. The FTC settlement cleared the way for Roche's $10.2 bil. acquisition of Corange, the parent company of Boehringer Mannheim and DePuy.

QUOTED. 10 April 2020. Shawn Patterson.

3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts